Search Results for: Semma

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc

Katarina-Le-Blanc

The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical …

Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »

New biotech Semma Therapeutics stem cell diabetes arena

Semma_05-4065

A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston …

New biotech Semma Therapeutics stem cell diabetes arena Read More »

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes

Doug Melton, Vertex, ViaCyte

When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …

ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »

Vertex upbeat on 1st stem cell therapy for diabetes trial participant

“While still early, these results support the continued progression of our VX-880 clinical studies, as well as future studies using our encapsulated islet cells, which hold the potential to be used without the need for immunosuppression,” said Bastiano Sanna, Ph.D., executive vice president and chief of cell and genetic therapies at Vertex.

It’s hard in the cell therapy field not to get excited even with bits of seemingly encouraging news but with N=1 reports we have to be very cautious and that’s the case with news from Vertex on their 1st stem cell therapy for diabetes trial participant. Vertex stem cell therapy for diabetes VX-880: N=1 This …

Vertex upbeat on 1st stem cell therapy for diabetes trial participant Read More »

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more

stem cell therapy for diabetes

The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta …

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

ViaCyte-CyT49-PSC

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the …

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

Stem cell & other science weekend reads: arteries, diabetes, iffy metaphors, & more

weekend-reads-include-this-paper-from-Eric-Olsons-lab

What are your weekend reads? Many of us scientists read up on specific articles over the weekend that caught our eye during the last week or two. Here are some of my weekend reads plus some other stuff that just generally looked really interesting or unusual. The list includes both primary papers and news articles …

Stem cell & other science weekend reads: arteries, diabetes, iffy metaphors, & more Read More »

ViaCyte & CRISPR Therapeutics team up to battle diabetes

ViaCyte, cell therapy for diabetes

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can develop an effective stem cell-based therapy for diabetes. You can see a press release on …

ViaCyte & CRISPR Therapeutics team up to battle diabetes Read More »